secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008665
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q1 revenue $15.5M (+10% YoY); narrows FY revenue guidance to $68-73M
--------------------------------------------------------------------------------

- Net loss of $(10.5)M or $(0.38)/share vs $(10.8)M or $(0.41)/share in Q1 2022.
- U.S. treatment session revenue rose 12% to $10.6M; shipped 49 NeuroStar systems.
- Full-year 2023 revenue guidance set at $68-73M; Q2 2023 revenue expected $17-18M.
- Amended SLR credit facility provides up to $60M at SOFR+5.65%, interest-only until March 2026.
- United Healthcare and BCBS of Mississippi updated policies to allow NPPs to prescribe TMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/0001558370-23-008665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000155837023008665/stim-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer